Thrasos Therapeutics Presents Preclinical Data Demonstrating THR-184 Prevents Loss Of Kidney Function Following Acute Ischemic Injury
6/3/2014 9:54:32 AM
MONTREAL--(BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat. Results of the studies were presented at the 51st European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress taking place in Amsterdam, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.
comments powered by